{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:18:09Z","timestamp":1767626289221,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,7]]},"DOI":"10.1182\/blood.2020008108","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:46:19Z","timestamp":1610567179000},"page":"3-5","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Stage I DLBCL: extranodal may mean extra radiation"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"first","affiliation":[{"name":"University of Miami"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2021010716361255900_B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.2020005112","article-title":"Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era","volume":"137","author":"Bobillo","year":"2021","journal-title":"Blood"},{"key":"2021010716361255900_B2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"2021010716361255900_B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","article-title":"Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation: a population-based study of 1575 cases","volume":"124","author":"Moller","year":"2004","journal-title":"Br J Haematol"},{"issue":"12","key":"2021010716361255900_B4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"2021010716361255900_B5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"2021010716361255900_B6","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021010716361255900_B7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"issue":"10216","key":"2021010716361255900_B8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2020","journal-title":"Lancet"},{"issue":"15 suppl","key":"2021010716361255900_B9","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA [abstract]","volume":"36","author":"Pfreundschuh","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021010716361255900_B10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/1\/3\/1795959\/bloodbld2020008108c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/1\/3\/1795959\/bloodbld2020008108c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:46:21Z","timestamp":1610567181000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/1\/3\/474790\/Stage-I-DLBCL-extranodal-may-mean-extra-radiation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008108","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}